Summary & Overview
HCPCS Level II J0207: Injection, Amifostine 500 mg
HCPCS Level II code J0207 denotes a 500 mg injection of amifostine, a cytoprotective agent used alongside chemotherapy or radiation to mitigate treatment-related toxicities. Nationally, accurate coding for supportive oncology drugs like amifostine affects claims processing, coverage determinations, and cost management across inpatient and outpatient infusion settings.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for amifostine administration, typical sites of service (hospital outpatient departments and infusion centers), and payer coverage considerations. The publication highlights benchmarks relevant to billing and utilization, recent policy or coverage updates where applicable, and common billing practices tied to HCPCS reporting for drug administration.
This report provides practical reference material for revenue cycle staff, oncology practice managers, and policy analysts seeking a national perspective on coding and coverage implications for J0207. Data not available in the input will be clearly identified in sections that require it.
Billing Code Overview
HCPCS Level II code J0207 represents an injection of amifostine, 500 mg. This service is a pharmacologic cytoprotective agent administered intravenously to reduce certain toxicities associated with chemotherapy and radiation therapy.
Service Type: Therapeutic drug administration (intravenous infusion/injection)
Typical Site of Service: Hospital outpatient department, infusion center, or oncology clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient scheduled to receive cytotoxic chemotherapy or intraoperative radiotherapy with a high risk of nephrotoxicity, severe mucositis, or other organ-specific toxicity for which amifostine is indicated as a cytoprotective agent. The patient arrives at an outpatient infusion center or hospital infusion suite (typical sites of service: outpatient hospital infusion center, freestanding infusion center, or inpatient hospital when given as part of a complex inpatient chemotherapy regimen). Prior to administration, nursing performs medication reconciliation, verifies height and weight for dosing, confirms baseline blood pressure and renal function, and obtains informed consent specific to antineoplastic supportive care. Amifostine (J0207, 500 mg vial) is reconstituted per institutional protocol and administered intravenously over the recommended infusion time with antiemetic and hydration support as ordered. Blood pressure is monitored frequently during and for a period after infusion due to risk of hypotension. Documentation includes indication, dose in mg, lot number, route (IV), start and stop times, vital sign monitoring, and any acute reactions. Common clinical workflow steps: physician order entry with indication and dose, pharmacy verification and preparation, bedside verification and administration by oncology-certified nursing staff, post-infusion monitoring and documentation, and billing using HCPCS Level II code J0207 with applicable modifiers to reflect payer-specific circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|